Report 3: Experience Negotiating Private Payer PLAs
PDCI Market Access (PDCI) and H3 Consulting (H3) recently launched the Private Payer Product Listing Agreement (PLA) Series, which provides the results of an online survey of a select group of Canadian private payers and manufacturers. The purpose of this survey, which was conducted between June 29, 2015 and July 17, 2015, was to enhance the understanding of the prevalence, objectives, and content of private payer PLAs in Canada.
This 3rd report presents the perspectives of those stakeholders who have negotiated private payer PLAs. Some highlights from this report include:
- Approximately 41% (i.e. 7 manufacturers and 4 payers) of the 27 survey respondents indicated that they have experience negotiating private payer PLAs.
- For those that were willing to provide clarity on the type of products for which they negotiated an agreement, the majority indicated they had negotiated agreements for specialty drugs while none indicated experience negotiating drugs for rare diseases.
- Most private payer PLA agreements were completed in 2015 but span back as far as 2012.
- The majority of the manufacturer respondents indicated the reason they negotiated an agreement was because they were requested by the private payer.
Please click here for a complimentary copy of the third report entitled, “Report 3: Experience Negotiating a Private Payer PLA”. Through the month of September, we are issuing the following four reports:
- Report 1: Negotiation-Naïve & No Interest in Negotiating a Private Payer PLA
- Report 2: Negotiation-Naïve & Interested in Negotiating a Private Payer PLA
- Report 3: Experience Negotiating Private Payer PLAs (NEW)
- Report 4: PLA Perspectives, Comparison and Contrast